Floatz logo

Erythropoietin Human Recombinant

Amyotrophic Lateral Sclerosis

Hanyang University Seoul HospitalPhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

151 Active assets in the Amyotrophic Lateral Sclerosis cohort.

Asset / SponsorPhaseRating
TAURURSODIOL
Amylyx Pharmaceuticals Inc.
Phase 3BBB
Tofersen
Biogen
Phase 4BBB
Riluzole
AB Science
Phase 4BB
Mexiletine
Bjorn Oskarsson, MD
Phase 4BB
DIACETYL(N(4)-METHYLTHIOSEMICARBAZONATO) COPPER (II)
Collaborative Medicinal Development Pty Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

Erythropoietin Human Recombinant is also rated in:

anemiaDormant
BBB
Indicative ·
78 / 100
View asset →
AngiogenesisDormant
BB
Indicative ·
69 / 100
View asset →
Acute StrokeDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →